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tionmedications are due to the availability of a variety of antipsychotics which are
widely used for both acute schizophrenia and as maintenance medications. This
cost estimate may help health care providers and policymakers better understand
the economic burden of schizophrenia and identify services associated with the
highest costs.
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OBJECTIVES: To estimate the IC for adult women with AD in the United States in
2006. METHODS: Females  17 years who reported AD were selected. A control
group was created using propensity score matching.The components of indirect
costs were annual national cost of missed work days for employed individuals,
annual national cost of other bed days for unemployed individuals, and the present
value of future productivity due to premature deaths. To calculate the number of
missedwork days attributable to AD, the unadjustedmean number ofmissedwork
days and other bed days for those without AD was multiplied by the regression
coefficient for AD from the multivariate regression minus the unadjusted mean
number of missed work days and other bed days for those without AD. Using the
number days attributable to AD and the MEPS sample weights for each individual,
the total cost of missed work days and other bed days attributable to AD in the
United States was estimated. Mortality costs were calculated as the present value
of future productivity due to premature deaths. The total amount of indirect costs
was estimated by adding the total from morbidity estimate to the total from the
mortality estimate. RESULTS: The morbidity costs was $8.13 billion and mortality
costs was $0.46 billion. CONCLUSIONS: Morbidity costs due to lost productivity
were the major costs of IC and indicate a significant financial burden that can be
reduced by disease management programs.
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OBJECTIVES: To examine healthcare cost patterns prior to and following dulox-
etine initiation in patients with major depressive disorder (MDD), focusing on pa-
tients whose dose was initially high or was titrated to high levels.METHODS: This
was a retrospective analysis of 10,987 patients aged 18 to 64 years treated in a
real-world clinical setting and enrolled in health insurance for the 6 months pre-
ceding and 12 months following initiation of duloxetine. Repeated measures and
pre-post analyses were used to examine longitudinal healthcare cost trajectories
before and after initiation of low- (60 mg/day), standard- (60 mg/day), and high-
(60mg/day) dose duloxetine. Classification and regression tree analysis was used
to identify factors influencing patient heterogeneity in healthcare cost outcomes
for patients whose doses were titrated to high levels. RESULTS: Low, standard, and
high doses of duloxetine were initiated for 29.6%, 60.9%, and 9.5% of patients,
respectively, with 13.7% received titrated high dose within 6 months duloxetine
initiation. Regardless of dose, total costs increased in the months leading to and
decreased in the months following initiation of treatment. Patients whose dose
was initially60 mg/day had higher costs both prior to and throughout the course
of treatment as compared to patients treated with standard-dose duloxetine. Fol-
lowing dose escalation to 60 mg/day, costs were higher for medication but lower
for inpatient services, resulting in total cost neutrality. Titration to high-dose ther-
apy was cost beneficial for patients with histories of a mental disorder and high
prior medical costs. CONCLUSIONS: Patients with MDD had cost increases leading
to and cost declines following initiation of duloxetine therapy. Patients treated
with60mg/day had higher healthcare costs both prior to and following initiation
compared to those treated with 60 mg/day. Increases in pharmacy costs associ-
ated with escalation to high-dose therapy were offset by reduced inpatient costs.
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OBJECTIVES:To compare real-world healthcare costs after initiation of second-line
antidepressant treatment with duloxetine vs. generic selective serotonin reuptake
inhibitors (SSRIs) for major depressive disorder (MDD). METHODS: Study sample
was selected from a de-identified U.S. privately-insured claims database (2005-
2009). Selection criteria: age 18-64 years,1MDDdiagnosis (ICD-9-CM: 296.2, 296.3)
in an inpatient setting or 2 MDD diagnoses in emergency room/outpatient set-
tings, initiation of an antidepressant treatment after a 3-monthwashout, initiation
of a second-line treatment with duloxetine or generic SSRI (defined as the index
date) no later than 90 days after the end of first-line treatment, continuous cover-
age eligibility from 6 months before the index date (baseline period) to 12 months
after the index date (study period). Using optimal matching on propensity scores
and baseline costs, 838 patients initiating second-line duloxetine were matched to
838 patients initiating second-line generic SSRI. McNemar tests were used to com-
pare proportions. Bias-corrected bootstrapping was used to compare healthcare
costs (reimbursement to providers for medical services and prescription drugs)
inflated to 2009 dollars. RESULTS: Before matching, second-line duloxetine com-
paredwith generic SSRI userswere older,more likely to be female, had ahigher rate
of chronic pain, and had higher baseline prescription drug costs and $2,967 higher
study period healthcare costs. Aftermatching, therewere no notable differences in
baseline characteristics and costs. Aftermatching, neither study period healthcare
costs ($11,342 vs. $10,328, p.2316) nor medical costs ($8,377 vs. $8,051 p.7063)
were significantly different between second-line duloxetine and generic SSRI us-
ers. Prescription drug costs were significantly higher for second-line duloxetine
users ($2,965 vs. $2,277, p.0001), largely due to differences in mental health-re-
lated drug costs ($1,605 vs. $1,008, p.0001).CONCLUSIONS:Controlling for patient
differences, this study found that second-line duloxetine users had similarmedical
costs and higher drug costs compared with second-line generic SSRI users.
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THE EFFECTIVENESS OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT
AMONG AETNA’S OPIOID DEPENDENT MEMBERS: AN ANALYSIS OF HEALTH
CARE COSTS AND SERVICE UTILIZATION
Tkacz J1, Un H2, Leader Jr. D2, Ruetsch C1
1Health Analytics, LLC, Columbia, MD, USA, 2Aetna Behavioral Health, Blue Bell, PA, USA
OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is an effec-
tive treatment for opioid dependence (OD), but may be considered cost-prohibitive
by patients and health plans who manage its use based on ingredient cost alone.
This analysis was conducted to estimate economic costs and benefits of B-MAT for
OD from the perspective of a health plan sponsor.METHODS: A longitudinal, mul-
tivariate analysis was conducted using service use claims data among a sample of
Aetnamembers with full benefit coverage and one ormore diagnoses of OD during
the 48 monthmeasurement period (Q1 2006 to Q4 2009). ODmembers treated with
B-MAT (n  725) were compared to members not treated with B-MAT (n  1410).
Two six-month measurement periods were constructed around the index date: a
sixmonth pre-period and a sixmonth post-period.RESULTS:During the six-month
post period, B-MATmembers filled an average of 0.29 (P 0.001)more prescriptions
and had an average of 0.21 more psychiatrist visits (P 0.001) than non B-MAT
members, but utilized significantly fewer behavioral health inpatient hospital ad-
missions (0.82), behavioral health hospital days (0.71), medical inpatient hospi-
tal days (0.39), and emergency room visits (0.31; P’s 0.001). Concerning health-
care costs, B-MATmembers spent $5305 less on inpatient hospital costs (P0.002),
$542 less on emergency room costs (P 0.016), and $6,378 less on total health care
costs per member compared to non B-MAT members (P 0.001). CONCLUSIONS:
Though B-MAT patients incur higher pharmacy costs, they use fewer expensive
health care services in other areas, resulting in an overall positive cost-benefit.
Assuming present results remain in direction and magnitude across other health
plans, and from year to year, health plans can experience considerable savings
using B-MAT as a first line of treatment for OD supported by outpatient services
such as office based providers and counselors.
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OBJECTIVES: To investigate the relationship between persistence with drug ther-
apy and treatment costs in patients with schizophrenia. METHODS: Paid claims
data from a commercial insurer was used to identify patients with schizophrenia.
The unit of observation was the drug treatment episode. A total of 21,570 episodes
were included in ordinary least squares (OLS) regressionmodels of post-treatment
cost as a function of alternative definitions of compliance adjusting for patient
demographics, drug use history, prior medical care use, schizophrenia diagnosis
and co-morbid medical conditions. RESULTS: Adding a second medication within
one year is the key factor in this study. When compared to patients achieving one
year of continuous therapy on the initial drug without switch or augment on a
second drug; patients completing one year of therapy on their initial drug while
adding an augmenting medication experienced increased drug costs by $1,565
(p0.0001) and increased medical costs of $6,583(p0.0001). Patients who did not
achieve compliance on their initial medication, but did achieve compliance on
their second medication exhibit higher total costs $11,381(p0.0001). Patients us-
ing less than one year of psychotropicmedication despite switching to or augment-
ing with a second drug experienced reduced drug costs, but also experienced in-
creased medical costs. Similarly, patients who discontinued their initial therapy
within one year but restart therapy using these medications also experienced re-
duced drug costs and increased medical costs. Finally, patients who quit their
initial and any other therapy within one year save drug costs but also experience
significantly higher medical costs. CONCLUSIONS: Compliance is associated with
significant reductions in medical costs only if the initial drug regimen is main-
tained for 12 months. On the other hand, patients using less than one year of
psychotropicmedication experienced reduced drug costs relative to themost com-
pliant patients(the comparison group), but also experienced increased medical
costs.
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OBJECTIVES: To assess the patterns of mental-health related medical care utiliza-
tion and medical costs in patients with schizophrenia initiating on either oral or
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